Our Work in
Antibiotic Research

For more than 80 years, MSD has contributed to the discovery and development of novel medicines and vaccines to combat infectious disease. Today, MSD is a global leader in antimicrobials with a proud heritage, broad portfolio and innovative pipeline.


MSD's Research Laboratories played a central role in the development of antimicrobials

MSD, in collaboration with Rutgers University, developed one of the first methods for mass production of penicillin

MSD markets a number of antibacterial, antifungal, and antiviral products and vaccines for the treatment or prevention of infectious diseases in markets around the globe


Maintaining active R&D programs to address unmet medical needs in the prevention and treatment of infectious disease

Monitoring trends in antibacterial resistance as exemplified by our longstanding commitment to surveillance studies

Supporting responsible use of antimicrobials to help slow development of resistance and preserve current therapeutic options

Advocating for improvements in regulatory guidance and financial incentives to support and accelerate innovation in the development of new antimicrobials, vaccines, services and solutions

MSD is one of the largest pharmaceutical companies with a continued focus on anti-infective research and development. We develop treatments for serious infections and promote appropriate use of these products. As such, the need for patient-centered antimicrobial stewardship (AMS) is fundamental to our work.

- Elizabeth D. Hermsen, Head of Global
Antimicrobial Stewardship, MSD


There is a critical need for solutions to manage the growing problem of antimicrobial resistance.


Research and innovation will lead to the development of new antibiotics.


Antimicrobial stewardship promotes the appropriate use of antimicrobials to reduce resistance.


Policies can help spur innovation and regulate the use of antibiotics.


In addition to our own antimicrobial research efforts, MSD also works with scientists across the world.

Through its MSD Innovation Network (MINt), the company actively collaborates with leading scientists in the antimicrobial field to investigate novel therapeutic targets, evaluate new pathways for drug targeting and develop novel tools and technologies. MSD has a number of ongoing collaborations with scientists at universities including Harvard, Yale and Princeton.

The Unique Role of Public Policy in Addressing Antimicrobial Resistance

Nicole Mahoney, director, Global Regulatory Policy, MSD, on how antimicrobial resistance is forcing policy makers to rethink the way diseases are managed, from how infections are diagnosed and tracked to how anti-infectives are developed and used.